Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

CRISPR Therapeutics AG

CRSP ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$53.55

▼ -0.81%

Market Cap $5.18B · Vol 251.43K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.18B

Mid Cap

Div Yield

N/A

EPS Growth

+13.79%

YoY

RSI (14)

79.30

Momentum

Beta

1.75

vs Market

52W High

$78.47

31.76% below

52W Low

$44.15

21.29% above

Volume

251.43K

Avg 481.92K

P/B

2.62

Price-to-book

ROE

-25.19%

Return on equity

Free Float

94.11%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, CRISPR Therapeutics AG (CRSP) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CRSP pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.06%

+6.12%

+6.14%

+0.90%

YTD

+2.12%

-8.96%

+10.00%

-57.75%

Financials & Valuation

TTM · Annual

Total Revenue	$3.51M
Net Income	$-581,599,000.00
Revenue Growth (YoY)	+1,041.37%
Gross Margin	100.00%
Operating Margin	-16,191.40%
Net Profit Margin	-16,569.77%
ROE	-25.19%
ROA · ROIC	-25.65% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1,343.50
P/B	2.62
P/FCF	N/A
EPS Growth	+13.79%
Outstanding Shares	96.69M

Technical Indicators

50-Day SMA	$52.30
200-Day SMA	$53.23
RSI (14)	79.30
Beta	1.75
52-Week High	$78.47
52-Week Low	$44.15

Volume Today	251.43K
Avg Daily Volume (30D)	481.92K
Relative Volume	0.52x
Volatility (10D)	39.81
Volatility (30D)	44.07
Free Float	94.11%

Analyst Consensus

BUY

Current Price $53.55

Mean Target $85.65

52W Low$44.15 52W High$78.47

Current

Target

$44.15 $78.47

Current Analyst target

+59.94% upside potential · 20 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00DBBGRY0

ISINCH0334081137

CountrySwitzerland

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.